Marinus Pharmaceuticals price target lowered to $4 from $13 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an Overweight rating on the shares. The company’s Phase III study of oral ganaxolone in tuberous sclerosis complex rare epilepsy did not meet the primary endpoint of significant difference in placebo-adjusted percent change in 28-day Tuberous Sclerosis Complex-associated seizure frequency in TSC patients on standard of care concomitant medicines, the analyst tells investors in a research note. The firm sees Marinus as a deep value opportunity in the hands of a potential strategic partner, with undervalued growth potential of ZTALMY.